Clinical Research Directory
Browse clinical research sites, groups, and studies.
Biomarkers for Risk Stratification in Lung Cancer
Sponsor: University of California, San Francisco
Summary
This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary populations to determine the ctDNA assay performance in a variety of clinical settings.
Official title: Circulating Tumor DNA for Risk Stratification in Lung Cancer Screening
Key Details
Gender
All
Age Range
40 Years - Any
Study Type
OBSERVATIONAL
Enrollment
590
Start Date
2017-12-17
Completion Date
2025-12-31
Last Updated
2025-03-20
Healthy Volunteers
Not specified
Interventions
Guardant Health ct-DNA LUNAR assay
Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.
Locations (3)
Zuckerberg San Francisco General Hospital and Trauma Center
San Francisco, California, United States
San Francisco VA Medical Center
San Francisco, California, United States
University of California, San Francisco
San Francisco, California, United States